IL-21 Products

NL001) and counterstained (green). View our protocol for Fluorescent ICC Staining of Non-adherent Cells." class="big_lightbox" target="_blank">

594-ML) stimulates proliferation in the NK-92 human natural killer lymphoma cell line in a dose-dependent manner (orange line). Proliferation elicited by Recombinant Mouse IL-21 (10 ng/mL) is neutralized (green line) by increasing concentrations of Mouse IL-21 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF594). The ND₅₀ is typically 0.2-2 µg/mL." class="big_lightbox" target="_blank">

594-ML) was serially diluted and captured by Goat Anti-Mouse IL‑21 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF594) coated on a Clear Polystyrene Microplate (Catalog # DY990). Goat Anti-Mouse IL‑21 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF594) was biotinylated and incubated with the protein captured on the plate. Detection of the standard curve was achieved by incubating Streptavidin-HRP (Catalog # DY998)" class="big_lightbox" target="_blank">

594-ML) was serially diluted and captured by Goat Anti-Mouse IL‑21 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF594) coated on a Clear Polystyrene Microplate (Catalog # DY990). Goat Anti-Mouse IL‑21 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF594) was biotinylated and incubated with the protein captured on the plate. Detection of the standard curve was achieved by incubating Streptavidin-HRP (Catalog # DY998)" class="big_lightbox" target="_blank">

BT-021-AFL) grades of Recombinant Human IL-21 as measured in a cell proliferation assay using B9 mouse hybridoma cells (orange and green, respectively)." class="big_lightbox" target="_blank">

CCM037) supplemented with IL-2 (Catalog # BT-002-GMP), IL-12 (Catalog # 10018-IL), IL-15 (Catalog # BT-015-GMP), IL-18 (Catalog # BT-018-GMP), and IL-21 (Catalog # BT-021-GMP) on plates coated with anti-human NKp46 (Catalog # MAB1850). PBMCs were plated to contain 1.8e4 NK cells as determined by flow cytometry on day 0. On day 5, 0.1e6 total cells were taken to seed a 6 well plate. Viability, expansion, and NK purity were analyzed on day 9, with n=5 +/- SEM. A: Total expansion of CD56+ CD3- cells between day 0 and day 9. B: PBMCs grown in ExCellerate NK Cell Expansion Media supplemented with cytokines exhibit viability greater than 80% at day 9." class="big_lightbox" target="_blank">

CCM037) supplemented with IL-2 (Catalog # BT-002-GMP), IL-12 (Catalog # 10018-IL), IL-15 (Catalog # BT-015-GMP), IL-18 (Catalog # BT-018-GMP), and IL-21 (Catalog # BT-021-GMP) on plates coated with anti-human NKp46 (Catalog # MAB1850). PBMCs were plated to contain 1.8e4 NK cells as determined by flow cytometry on day 0. On day 5, 0.1e6 total cells were taken to seed a 6 well plate. Viability, expansion, and NK purity were analyzed on day 9, with n=5 +/- SEM for day 9; n=1 for day 0. A: Purity of NK cells at day 9. B: NK ExCellerate media preferentially expands CD56+ NK cells. Percentage of CD56+ cells in culture rose from less than 10% in both donors to more than 60% by day 9." class="big_lightbox" target="_blank">